Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemia

3 Jun 2025

Abstract excerpt

Introduction: Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for most children with juvenile myelomonocytic leukemia (JMML), but overall survival remains poor at 50%. Given its rarity and heterogeneity, there is no standard HCT conditioning regimen for JMML. Methods: Retrospective study of consecutive patients with JMML who underwent HCT using a busulfan/ melphalan...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40530013
DOI: 10.3389/fonc.2025.1541192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemiaPMID 40530013Read ↗

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell TransplantationSemantic proximity Read ↗

Diagnosis and treatment of juvenile myelomonocytic leukemiaSemantic proximity Read ↗

[Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].Semantic proximity Read ↗

Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.Semantic proximity Read ↗

Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.Semantic proximity Read ↗

Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.Semantic proximity Read ↗

Current Treatment of Juvenile Myelomonocytic LeukemiaSemantic proximity Read ↗

Molecular basis of juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemiaSemantic proximity Read ↗

Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.Semantic proximity Read ↗

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.Semantic proximity Read ↗

Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.